Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 18/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.34 |
| ▸ | KDR | P35968 | 5/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783949 | 0.86 | FGFR1 (0.47) | MEN1KMT2AFGFR1FGFR4KDR | |
| SCHEMBL21761869 | 0.86 | FGFR1 (0.38) | FGFR1FGFR4AKT1AKT2PDGFRB | |
| SCHEMBL21783951 | 0.85 | MEN1 (0.36) | MEN1KMT2AFGFR1FGFR4KDR | |
| SCHEMBL23328278 | 0.84 | FGFR1 (0.34) | MEN1KMT2AFGFR1FGFR4KDR | |
| SCHEMBL23328708 | 0.82 | FGFR1 (0.50) | KMT2AFGFR1FGFR4KDRFGFR2 | |
| SCHEMBL23328623 | 0.80 | FGFR1 (0.37) | MEN1KMT2AFGFR1FGFR2AKT1 | |
| SCHEMBL29545501 | 0.75 | FGFR1 (0.38) | MEN1KMT2AFGFR1FGFR4KDR | |
| SCHEMBL16246296 | 0.75 | FGFR1 (0.38) | MEN1KMT2AFGFR1FGFR4KDR | |
| SCHEMBL23328261 | 0.74 | FGFR1 (0.42) | FGFR1FGFR4KDR | |
| SCHEMBL23328284 | 0.74 | FGFR1 (0.39) | FGFR1FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | MEN1 4125/4885KMT2A 3253/4885FGFR1 1/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | MEN1 4490/4885KMT2A 3272/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.